Literature DB >> 28222018

Analytical performance and diagnostic accuracy of six different faecal calprotectin assays in inflammatory bowel disease.

Matthijs Oyaert1, An Boel1, Julie Jacobs1, Stefanie Van den Bremt1, Maxime De Sloovere1, Hilde Vanpoucke1, Lieve Van Hoovels1.   

Abstract

BACKGROUND: We evaluated the analytical performance of six different faecal calprotectin immunoassays together with their diagnostic accuracy in the discrimination between functional and organic bowel disorders.
METHODS: The faecal samples were obtained from inflammatory bowel disease patients (n=27) at the time of diagnosis [Crohn's disease (n=15), colitis ulcerosa (n=12)], gastroenterologic disease control patients (n=52) and rheumatologic disease control patients (n=26). All individuals included in the study underwent a concurrent ileocolonoscopy. Analytical performance (imprecision, accuracy, carry-over, correlation and agreement) and diagnostic accuracy (sensitivity, specificity, likelihood ratios) of the different assays were evaluated.
RESULTS: All methods demonstrated good analytical performance, but within-run and total imprecision varied depending on the assay methodology used. Using Passing Bablok and Bland-Altman analyses, low quantitative agreement was observed between the assays. All assays showed excellent diagnostic accuracy, with areas under the receiver operating characteristic curves (ROC) ranging from 0.974 to 0.998. The AUCs were not significantly different between assays (p>0.05). Diagnostic sensitivity at the cut-off at a fixed specificity of 75% ranged from 95.2% to 100%. Introduction of multiple result intervals increased the clinical interpretation of all the assays.
CONCLUSIONS: Analytical and diagnostic performance of the evaluated faecal calprotectin assays is good, but numerical values differ substantially between the assays necessitating the use of different clinical cut-offs. Introduction of multiple result intervals aids in clinical decision-making.

Entities:  

Keywords:  faecal calprotectin; immunoassays; inflammatory bowel disease

Mesh:

Substances:

Year:  2017        PMID: 28222018     DOI: 10.1515/cclm-2016-1012

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  13 in total

Review 1.  Comparing outcomes from tailored meta-analysis with outcomes from a setting specific test accuracy study using routine data of faecal calprotectin testing for inflammatory bowel disease.

Authors:  Karoline Freeman; Brian H Willis; Ronan Ryan; Sian Taylor-Phillips; Aileen Clarke
Journal:  BMC Med Res Methodol       Date:  2022-07-12       Impact factor: 4.612

2.  Fecal Calprotectin May Predict Adverse Pregnancy-Related Outcomes in Patients with Inflammatory Bowel Disease.

Authors:  Parul Tandon; Eugenia Y Lee; Cynthia Maxwell; Lara Hitz; Lindsy Ambrosio; Levinus Dieleman; Brendan Halloran; Karen Kroeker; Vivian M Huang
Journal:  Dig Dis Sci       Date:  2020-06-12       Impact factor: 3.199

3.  International consensus on methodological issues in standardization of fecal calprotectin measurement in inflammatory bowel diseases.

Authors:  Ferdinando D'Amico; David T Rubin; Paulo Gustavo Kotze; Fernando Magro; Britta Siegmund; Taku Kobayashi; Pablo A Olivera; Peter Bossuyt; Lieven Pouillon; Edouard Louis; Eugeni Domènech; Subrata Ghosh; Silvio Danese; Laurent Peyrin-Biroulet
Journal:  United European Gastroenterol J       Date:  2021-05-07       Impact factor: 4.623

4.  Analytical evaluation of a fully automated immunoassay for faecal calprotectin in a paediatric setting.

Authors:  Britta Noebauer; Lejla Ramic; Andrea Konstantin; Christina Zachbauer; Elisa Einwallner
Journal:  Biochem Med (Zagreb)       Date:  2017-10-15       Impact factor: 2.313

5.  Analytical and clinical performance of the fully-automated LIAISONXL calprotectin immunoassay from DiaSorin in IBD patients.

Authors:  R Vicente-Steijn; J M Jansen; R Bisheshar; I-A Haagen
Journal:  Pract Lab Med       Date:  2020-06-24

Review 6.  From bench to bedside: Fecal calprotectin in inflammatory bowel diseases clinical setting.

Authors:  Maria Gloria Mumolo; Lorenzo Bertani; Linda Ceccarelli; Gabriella Laino; Giorgia Di Fluri; Eleonora Albano; Gherardo Tapete; Francesco Costa
Journal:  World J Gastroenterol       Date:  2018-09-07       Impact factor: 5.742

7.  Faecal calprotectin to detect inflammatory bowel disease: a systematic review and exploratory meta-analysis of test accuracy.

Authors:  Karoline Freeman; Brian H Willis; Hannah Fraser; Sian Taylor-Phillips; Aileen Clarke
Journal:  BMJ Open       Date:  2019-03-08       Impact factor: 2.692

8.  Fecal calprotectin in healthy children aged 4-16 years.

Authors:  María Roca; Ana Rodriguez Varela; Eva Carvajal; Ester Donat; Francisco Cano; Ana Armisen; Maria Jose Vaya; Helena Ekoff; David Hervas; Niclas Rydell; Carmen Ribes-Koninckx
Journal:  Sci Rep       Date:  2020-11-25       Impact factor: 4.379

9.  Faecal calprotectin determination: impact of preanalytical sample treatment and stool consistency on within- and between-method variability.

Authors:  Gordana Juricic; Tina Brencic; Andrea Tesija-Kuna; Milena Njegovan; Lorena Honovic
Journal:  Biochem Med (Zagreb)       Date:  2019-02-15       Impact factor: 2.313

10.  Head to head comparison of two commercial fecal calprotectin kits as predictor of Mayo endoscopic sub-score and mucosal TNF expression in ulcerative colitis.

Authors:  Rasmus Goll; Richard Heitmann; Øystein Kittel Moe; Katrine Carlsen; Jon Florholmen
Journal:  PLoS One       Date:  2019-12-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.